Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals is the leading independent European antisense oligonucleotide (ASO) drug discovery and development company. Secarna’s mission is to leverage its proprietary LNAplus™ ASO discovery platform to discover, research and develop highly specific, safe and efficacious antisense therapies addressing a variety of targets deemed undruggable by current approaches to patients in need. Secarna seeks to establish ASO therapeutics as the third pillar in drug development, next to small molecules and antibodies, and expand the universe of druggable targets. Combining technical excellence with antisense drug discovery and development expertise supported by a global network of highly recognized KOLs, Secarna is paving the path for a new generation of ASO therapeutics.
Secarna Pharmaceuticals at a glance:
|Field of Activity
|Secarna has built a rich, multifaceted pipeline of highly specific, safe and efficacious 3rd generation ASO therapies addressing high unmet medical needs in the areas of oncology and inflammatory/fibrotic, viral, neurodegenerative, neurodevelopmental, neuromuscular as well as cardiometabolic diseases. The Company has progressed its in-house programs up to pre-clinical POC, while first partnered programs have already reached clinical development stage. Secarna plans to move selected in-house programs into IND-enabling studies and subsequently into clinical phase 1/2 studies by 2024 and is actively looking to partner further existing projects.
|Ownership Structure and Financing
|Privately held. Secarna generates revenues from technology access fees, R&D funding, license fees, and milestone payments
|Secarna’s LNAplus™ platform and ASOs have been validated by in-house projects and in collaborations with top tier industry as well as academic partners. Partnerships include Denali Therapeutics, Inc., Evotec SE, Firebrand Therapeutics, Inc., Guangzhou Sun Yat-sen University (SYSU), Lipigon Pharmaceuticals AB and SciNeuro Pharmaceuticals. The Company‘s versatile business model is set to accommodate the best mix of in-house development and partner collaborations, addressing the core pillars of a successful partnership portfolio.
|Unique Selling Point
|Proprietary 3rd generation ASO platform LNAplus™ encompassing all aspects of drug discovery and pre-clinical development, proven to be fast, reliable, scalable, efficient at developing a uniquely integrated workflow. Oligofyer™ bioinformatics and LNA Vit(r)ox™ screening system, best-in-class high throughput screening and target-specific functional assays.
|Date of Incorporation/Number of Employees
|Am Klopferspitz 19
|+49 89 215 46 375